Laurie H. Sehn, MD, MPH, on HGBCL With Comorbidities: Upfront Therapies
Pan Pacific Lymphoma Conference 2018
Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses the challenges of treating high-grade B-cell lymphoma in older patients and those with comorbidities. Several strategies have been devised, but more research is needed as well as more options for novel therapies.
R. Gregory Bociek, MD, of the University of Nebraska Medical Center, discusses the controversial topic of euthanasia and physician-assisted suicide.
John G. Gribben, MD, DSc, of the Barts Cancer Institute, discusses how understanding the role of the tumor microenvironment can help identify treatment targets, including combination therapies, and improve outcome for patients with indolent lymphomas.
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses promising pathways for inhibitors—BTK, PI3K, EZH2, bcl-2—and the clinical trials for single agents and combinations that suggest their potential for lymphoma treatment.
Sagar Lonial, MD, of the Emory University School of Medicine, discusses the importance of planning for relapse based on the treatment a patient has received, new targets for refractory myeloma, and the role of cellular therapy.
Kieron M. Dunleavy, MD, of George Washington University, discusses the need for drug combinations to improve lymphoma therapy, despite unexpected toxicities, as our understanding of the molecular biology grows.